Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

3.86 (USD) • At close July 1, 2025
Bedrijfsnaam Corvus Pharmaceuticals, Inc.
Symbool CRVS
Munteenheid USD
Prijs 3.86
Beurswaarde 297,662,356
Dividendpercentage 0%
52-weken bereik 1.75 - 10
Industrie Biotechnology
Sector Healthcare
CEO Dr. Richard A. Miller M.D.
Website https://www.corvuspharma.com

An error occurred while fetching data.

Over Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818,

Vergelijkbare Aandelen

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

0.023 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

7.34 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

16.15 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

2.01 USD

Venus Concept Inc. logo

Venus Concept Inc.

VERO

2.62 USD

Accelerate Diagnostics, Inc. logo

Accelerate Diagnostics, Inc.

AXDX

0.034 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

2.42 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

2.59 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)